Short- and long-term results after thrombolytic treatment of deep venous thrombosis
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Objectives The goal of this study was to assess the short- and long-term efficacy of different thrombolytic therapy regimens in patients with leg or pelvic deep venous thrombosis (DVT).Background It is unclear whether locoregional or systemic thrombolysis is superior in treating acute leg DVT or even whether lysis is more effective than anticoagulation therapy in preventing postthrombotic syndrome.Methods A total of 250 patients averaging 40 years of age with acute DVT were randomized into five groups to receive full heparinization (1,000 IU/h) and compression treatment, with four groups also administered locoregional tissue plasminogen activator (20 mg/day) or urokinase (100,000 IU/day) or systemic streptokinase (3,000,000 IU daily) or urokinase (5,000,000 IU daily). All groups then received anticoagulation and compression treatment for one year. Primary efficacy criteria included the change after one year in the number of closed vein segments and the occurrence of postthrombotic syndrome.Results Systemic thrombolytic therapy significantly reduced the number of closed vein segments after 12 months in patients with acute DVT compared with conventional treatment (p < 0.05). Postthrombotic syndrome also occurred with less frequency in systemically treated patients versus controls (p < 0.001). High-dose thrombolysis led to better rates of complete recanalization after seven days (p < 0.01) than locoregional lysis. However, 12 patients receiving thrombolysis (9 systemic, 3 local) suffered major bleeding complications; 9 patients on systemic treatment developed pulmonary emboli.Conclusions Systemic thrombolytic treatment for acute DVT achieved a significantly better short- and long-term clinical outcome than conventional heparin/anticoagulation therapy but at the expense of a serious increase in major bleeding and pulmonary emboli. Given the inherent risks for such serious complications, systemic thrombolysis, although effective, should be used selectively in limb-threatening thrombotic situations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, thrombolytics were systemically infused, except in 4 trials, including the recently published ATTRACT trial, in which thrombolytics were catheter directed 133,134,146,148 and 2 trials in which thrombolytics were locoregionally infused. 141,142”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [142]
In the citing paper
“In 4 trials, 214-217 thrombolysis was catheter directed, whereas in 1, 142 it was locoregionally infused.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [142]
In the citing paper
“Weidentified 3 systematic reviews 119,212,213 and 5 controlled trials (n 5 427). 142,214-217”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [142]
Citations
Cites
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
(1995) · Choice Reviews Online · doi:10.5860/choice.33-0365 · Cited by 793
Thrombolytic Therapy: Current Status
Marder, V. J., & Sherry, S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182306 · Cited by 539
Elliot, M. S., Immelman, E. J., Jeffery, P., Benatar, S. R., Funston, M. R., Smith, J. A., Shepstone, B. J., Ferguson, A. D., Jacobs, P., Walker, W., et al. (1979) · Journal of British Surgery · doi:10.1002/bjs.1800661203 · Cited by 287
Arnesen, H., Høiseth, A. D., & Ly, B. E. (1982) · PubMed · Cited by 214
Thrombolytic Therapy: Current Status
Marder, V. J., & Sherry, S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806163182406 · Cited by 213
Arnesen, H., Høiseth, A., & Ly, B. (1982) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1982.tb01904.x · Cited by 209
Vv, K., & Lawrence, D. (1985) · PubMed · Cited by 142
Thrombolytic therapy for deep venous thrombosis: a clinical review.
Comerota, A. J., & Aldridge, S. C. (1993) · PubMed · Cited by 140
Deep Vein Thrombosis Treated With Streptokinase or Heparin: Follow-Up of a Randomized Study
Common, H. H., Seaman, A. J., Rösch, J., Porter, J. M., & Dotter, C. T. (1976) · Angiology · doi:10.1177/000331977602701105 · Cited by 92
Research works printed but not linked: 3
- Heimig, 1992, Lyseblock-Technik, Vasa, 21, 289
- Timmermann, 1992, Lokale fibrinolytische Therapie (PLL) der tiefen Beinvenenthrombose mit rt-PA, Phlebol, 21, 205
- Cossio, 1992, Erprobung einer neuen Methode in der lokoregionalen Behandlung mit Urokinase bei tiefer Venenthrombose (TVT), Phlebol, 21, 119
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“Summary of the evidence We identified 3 systematic reviews(119,212,213) and 5 controlled trials (n 5 427).(142,214-217) Trials included individuals with objectively confirmed symptomatic proximal DVT.”
BackgroundMethodNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Metadata
- Authors
- Schweizer, J., Kirch, W., Koch, R., Elix, H., Hellner, G., Forkmann, L., & Graf, A.
- Affiliations
- Klinikum Chemnitz (DE)
- Technische Universität Dresden (DE)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Corresponding author
- Schweizer, Johannes
- ORCID
- Koch, Rainer
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2000-10
- Volume
- 36
- Issue
- 4
- Pages
- 1336-1343
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2016609963
- Cited by
- 172
- References
- 30
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 12 · 2019: 7 · 2018: 8 · 2017: 5 · 2016: 8 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4671 d)
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- deep vein thrombosis, thrombolysis, intravenous thrombolysis, tissue plasminogen activator, urokinase, streptokinase, post-thrombotic syndrome, venous recanalization, heparin anticoagulation, compression therapy, bleeding complications, pulmonary embolism
- MeSH terms
- Adult, Anticoagulants, Blood Flow Velocity, Drug Therapy, Combination, Female, Follow-Up Studies, Heparin, Humans, Infusions, Intravenous, Male, Middle Aged, Phlebography, Tissue Plasminogen Activator, Plasminogen Activators, Safety, Streptokinase, Urokinase-Type Plasminogen Activator, Thrombolytic Therapy, Ultrasonography, Doppler, Color, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short- and long-term results after thrombolytic treatment of deep venous thrombosis. https://app.cochat.ai/papers/10.1016/s0735-1097(00)00863-9
- The paper
- Schweizer, J., Kirch, W., Koch, R., Elix, H., Hellner, G., Forkmann, L., & Graf, A. (2000). Short- and long-term results after thrombolytic treatment of deep venous thrombosis. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(00)00863-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.